Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
根據最新的財務報表(Form-10K),Apimeds Pharmaceuticals US Inc 的總資產為 $0,淨損失為 $0
APUS 的關鍵財務比率是什麼?
Apimeds Pharmaceuticals US Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Apimeds Pharmaceuticals US Inc 的收入按細分市場或地理位置如何劃分?
Apimeds Pharmaceuticals US Inc の最大収益セグメントは Other で、最新の利益発表における収益は -159,000,000 です。地域別に見ると、North America Residential が Apimeds Pharmaceuticals US Inc の主要市場であり、収益は 7,005,000,000 です。
Apimeds Pharmaceuticals US Inc 是否盈利?
いいえ,根據最新的財務報表,Apimeds Pharmaceuticals US Inc 的淨損失為 $0